124 related articles for article (PubMed ID: 33328104)
1. Design, synthesis and evaluation of novel thienopyrimidine-based agents bearing diaryl urea functionality as potential inhibitors of angiogenesis.
Faraji A; Oghabi Bakhshaiesh T; Hasanvand Z; Motahari R; Nazeri E; Boshagh MA; Firoozpour L; Mehrabi H; Khalaj A; Esmaeili R; Foroumadi A
Eur J Med Chem; 2021 Jan; 209():112942. PubMed ID: 33328104
[TBL] [Abstract][Full Text] [Related]
2. Exploration of carbamide derived pyrimidine-thioindole conjugates as potential VEGFR-2 inhibitors with anti-angiogenesis effect.
Sana S; Reddy VG; Bhandari S; Reddy TS; Tokala R; Sakla AP; Bhargava SK; Shankaraiah N
Eur J Med Chem; 2020 Aug; 200():112457. PubMed ID: 32422489
[TBL] [Abstract][Full Text] [Related]
3. Design and synthesis of thienopyrimidine urea derivatives with potential cytotoxic and pro-apoptotic activity against breast cancer cell line MCF-7.
Abdelhaleem EF; Abdelhameid MK; Kassab AE; Kandeel MM
Eur J Med Chem; 2018 Jan; 143():1807-1825. PubMed ID: 29133058
[TBL] [Abstract][Full Text] [Related]
4. Design, synthesis and biological evaluation of novel thieno[3,2-d]pyrimidine derivatives containing diaryl urea moiety as potent antitumor agents.
Liu Z; Wang Y; Lin H; Zuo D; Wang L; Zhao Y; Gong P
Eur J Med Chem; 2014 Oct; 85():215-27. PubMed ID: 25086238
[TBL] [Abstract][Full Text] [Related]
5. New 2,4-disubstituted-2-thiopyrimidines as VEGFR-2 inhibitors: Design, synthesis, and biological evaluation.
Abdel-Mohsen HT; Girgis AS; Mahmoud AEE; Ali MM; El Diwani HI
Arch Pharm (Weinheim); 2019 Nov; 352(11):e1900089. PubMed ID: 31463965
[TBL] [Abstract][Full Text] [Related]
6. Design and Synthesis of Novel Thiazolo[5,4-d]pyrimidine Derivatives as Potential Angiogenesis Inhibitors.
Xue WJ; Du JY; Deng YH; Yan ZH; Liu JP; Liu Y; Sun LP
Chem Biodivers; 2019 Aug; 16(8):e1900232. PubMed ID: 31287621
[TBL] [Abstract][Full Text] [Related]
7. Novel thienopyrimidine derivatives as dual EGFR and VEGFR-2 inhibitors: design, synthesis, anticancer activity and effect on cell cycle profile.
Mghwary AE; Gedawy EM; Kamal AM; Abuel-Maaty SM
J Enzyme Inhib Med Chem; 2019 Dec; 34(1):838-852. PubMed ID: 30919701
[TBL] [Abstract][Full Text] [Related]
8. Thienopyrimidine-based agents bearing diphenylurea: Design, synthesis, and evaluation of antiproliferative and antiangiogenic activity.
Mohammadian E; Oghabi Bakhshaiesh T; Jouyban A; Nazeri E; Hasanvand Z; Moghimi S; Motahari R; Firoozpour L; Bijanzadeh H; Alizadeh Sani M; Hosseinzadeh E; Esmaeili R; Foroumadi A
Arch Pharm (Weinheim); 2023 Mar; 356(3):e2200349. PubMed ID: 36408898
[TBL] [Abstract][Full Text] [Related]
9. Structure-activity relationship studies of pyrazolo[3,4-d]pyrimidine derivatives leading to the discovery of a novel multikinase inhibitor that potently inhibits FLT3 and VEGFR2 and evaluation of its activity against acute myeloid leukemia in vitro and in vivo.
Yang LL; Li GB; Ma S; Zou C; Zhou S; Sun QZ; Cheng C; Chen X; Wang LJ; Feng S; Li LL; Yang SY
J Med Chem; 2013 Feb; 56(4):1641-55. PubMed ID: 23362959
[TBL] [Abstract][Full Text] [Related]
10. Phenyl and Diaryl Ureas with Thiazolo[5,4-d]pyrimidine Scaffold as Angiogenesis Inhibitors: Design, Synthesis and Biological Evaluation.
Xue WJ; Deng YH; Yan ZH; Liu JP; Liu Y; Sun LP
Chem Biodivers; 2019 Apr; 16(4):e1800493. PubMed ID: 30688404
[TBL] [Abstract][Full Text] [Related]
11. Pyrimidinylacetamide-based 2-pyridylureas as Angiogenesis Inhibitors: Design, Synthesis and Biological Evaluation.
Deng YH; Yan ZH; Liu JP; Liu Y; Sun LP
Arch Med Res; 2017 May; 48(4):333-342. PubMed ID: 28882321
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis, and biological evaluation of thieno[2,3-d]pyrimidine derivatives as novel dual c-Met and VEGFR-2 kinase inhibitors.
Li J; Gu W; Bi X; Li H; Liao C; Liu C; Huang W; Qian H
Bioorg Med Chem; 2017 Dec; 25(24):6674-6679. PubMed ID: 29146452
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis and biological evaluation of a new thieno[2,3-
Sharaky M; Kamel M; Aziz MA; Omran M; Rageh MM; Abouzid KAM; Shouman SA
J Enzyme Inhib Med Chem; 2020 Dec; 35(1):1641-1656. PubMed ID: 32781854
[TBL] [Abstract][Full Text] [Related]
14. Novel 5-substituted, 2,4-diaminofuro[2,3-d]pyrimidines as multireceptor tyrosine kinase and dihydrofolate reductase inhibitors with antiangiogenic and antitumor activity.
Gangjee A; Zeng Y; Ihnat M; Warnke LA; Green DW; Kisliuk RL; Lin FT
Bioorg Med Chem; 2005 Sep; 13(18):5475-91. PubMed ID: 16039863
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis and biological evaluation of pyrimidine-based derivatives as VEGFR-2 tyrosine kinase inhibitors.
Sun W; Hu S; Fang S; Yan H
Bioorg Chem; 2018 Aug; 78():393-405. PubMed ID: 29677483
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis and molecular modeling study of certain VEGFR-2 inhibitors based on thienopyrimidne scaffold as cancer targeting agents.
Ghith A; Youssef KM; Ismail NSM; Abouzid KAM
Bioorg Chem; 2019 Mar; 83():111-128. PubMed ID: 30343204
[TBL] [Abstract][Full Text] [Related]
17. Structure-activity relationships of 2, 4-disubstituted pyrimidines as dual ERα/VEGFR-2 ligands with anti-breast cancer activity.
Luo G; Tang Z; Lao K; Li X; You Q; Xiang H
Eur J Med Chem; 2018 Apr; 150():783-795. PubMed ID: 29587221
[TBL] [Abstract][Full Text] [Related]
18. Discovery of 6-Arylurea-2-arylbenzoxazole and 6-Arylurea-2-arylbenzimidazole Derivatives as Angiogenesis Inhibitors: Design, Synthesis and in vitro Biological Evaluation.
Zi M; Liu F; Wu D; Li K; Zhang D; Zhu C; Zhang Z; Li L; Zhang C; Xie M; Lin J; Zhang J; Jin Y
ChemMedChem; 2019 Jul; 14(13):1291-1302. PubMed ID: 31131561
[TBL] [Abstract][Full Text] [Related]
19. Identification of new pyrrolo[2,3-d]pyrimidines as potent VEGFR-2 tyrosine kinase inhibitors: Design, synthesis, biological evaluation and molecular modeling.
Adel M; Serya RAT; Lasheen DS; Abouzid KAM
Bioorg Chem; 2018 Dec; 81():612-629. PubMed ID: 30248512
[TBL] [Abstract][Full Text] [Related]
20. Novel pyrazolopyrimidine urea derivatives: Synthesis, antiproliferative activity, VEGFR-2 inhibition, and effects on the cell cycle profile.
Kassab AE; El-Dash Y; Gedawy EM
Arch Pharm (Weinheim); 2020 Apr; 353(4):e1900319. PubMed ID: 32091161
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
